27th Aug 2019 16:45
(Alliance News) - 4D Pharma PLC said Tuesday that it has appointed Sandy Macrae as an independent non-executive director with immediate effect.
Macrae currently serves as president & chief executive officer of US-listed Sangamo Therapeutics Inc, a genomic medicine company active in developing cell and gene therapies across a range of rare and large indications. Macrae has over 20 years of experience in the pharmaceutical industry, with a combination of scientific, medical and commercial expertise.
Shares in 4D Pharma closed up 2.6% at 80.00 pence each in London on Tuesday.
Related Shares:
DDDD.L